How to Market Prescription Drugs While Staying Compliant
How to market prescription drugs compliantly: the rules that apply, review, risky digital areas, privacy, transparency, and daily habits.
The short answer
To market prescription drugs compliantly in the US, keep every claim consistent with the FDA-approved label, present benefits and risks in balance, route all promotional material through medical, legal, and regulatory review, follow privacy law for any data used in targeting and tracking, report transfers of value to HCPs as required, and monitor live campaigns for issues such as adverse events in comments. Compliance works best as an operating habit, not a final gate.
Compliance in pharma marketing is often described as a list of things you cannot do. It is more useful to see it as a set of habits that let a team move quickly without creating risk. This guide opens a series on the operating side of compliance.
The rules that apply
| Area | Main source | What it governs |
|---|---|---|
| Promotion content | FDA (OPDP), 21 CFR Part 202 | Claims, balance, risk presentation |
| Unapproved uses | FDA | No promotion of off-label uses. See off-label risk |
| HCP interactions | Anti-kickback statute, PhRMA Code, OIG guidance | Payments, meals, speaker programs |
| Transparency | Open Payments and state laws | Reporting transfers of value. See Open Payments vs. aggregate spend |
| Privacy | HIPAA where applicable, FTC, state laws | Data in targeting and tracking |
| Platforms | Google, Meta, and others | Health ad policies and certification |
| Safety | FDA postmarketing requirements | Adverse event reporting. See AE monitoring |
The core content rules
- Consistent with the label. Claims must not go beyond approved indications and data.
- Fair balance. Benefits and risks presented in comparable prominence.
- Not misleading. By statement, omission, or presentation.
- Substantiated. Evidence for every claim.
- Required information. For example, the major statement and adequate provision for broadcast DTC.
The review process
Most companies use a review committee of medical, legal, and regulatory reviewers. Efficient teams:
- Submit complete materials with references.
- Use pre-approved claim libraries and modular content.
- Bring reviewers in early for new formats.
- Track review rounds and reasons for rejection.
See MLR review tools and workflow and MLR for programmatic media.
Risky areas in digital media
- Small formats where risk information is hard to present.
- Social media, especially user comments and influencer content. See influencer rules.
- Dynamic creative that assembles messages automatically. See dynamic targeting rules.
- Search ads with character limits.
- Targeting that implies an off-label audience.
- Website tracking on condition pages.
Privacy
Data used for targeting and measurement must follow HIPAA where applicable, FTC rules, and state consumer health data laws. Review tags on websites and the consent basis for every audience.
Enforcement trends
FDA's Office of Prescription Drug Promotion issues untitled and warning letters, published on FDA's website. In September 2025, FDA announced a broader enforcement push on misleading drug advertising. Reading recent letters is one of the fastest ways to learn what regulators focus on. See OPDP letters: lessons for media teams.
Operating habits
- Keep a claims library with references and approval dates.
- Expire materials on a schedule and re-review.
- Log every live placement and its approved version.
- Monitor comments and mentions for adverse events.
- Train media partners on your rules.
Common mistakes
- Treating compliance as the last step.
- Approving a static ad, then running it in a dynamic format that changes it.
- Forgetting partner-run content, such as influencer posts or telehealth pages.
- Tracking tags added to condition pages without review.
Practical takeaway
Pick one live campaign and trace every placement back to an approved version and approval date. Any placement you cannot trace is a gap in your process, whatever its content.
Frequently asked questions
What are the main rules for prescription drug marketing in the US?
FDA rules on prescription drug advertising and promotional labeling, FTC rules on health data and some claims, anti-kickback and transparency rules for interactions with HCPs, privacy laws, and platform policies.
What is MLR review?
Medical, legal, and regulatory review of promotional materials before use. Reviewers check claims, evidence, balance, and legal risk.
What happens if a drug ad breaks the rules?
FDA can issue untitled or warning letters requiring corrective action. Other regulators and courts may act on privacy, fraud, or kickback issues.
Sources
- FDA, Office of Prescription Drug Promotion (OPDP)
- eCFR, 21 CFR Part 202, Prescription Drug Advertising
- FDA, Presenting Risk Information in Prescription Drug and Medical Device Promotion
- CMS, Open Payments
- HHS, Use of Online Tracking Technologies by HIPAA Covered Entities and Business Associates
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.